NCT00482495已完成2 期
A Phase II Trial of Bevacizumab in Patients With Relapsed or Refractory Multiple Myeloma
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- Mayo Clinic
- 入组人数
- 42
- 试验地点
- 2
- 主要终点
- Confirmed hematologic response
研究概览
简要总结
RATIONALE: Monoclonal antibodies, such as bevacizumab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them. Bevacizumab may also stop the growth of multiple myeloma by blocking blood flow to the cancer.
PURPOSE: This phase II trial is studying how well bevacizumab works in treating patients with relapsed or refractory multiple myeloma.
详细描述
OBJECTIVES:
Primary
- Determine the hematologic response rate in patients with relapsed or refractory multiple myeloma treated with bevacizumab.
- Determine the proportion of patients who are progression free and have not failed treatment after 1 year.
Secondary
- Determine the toxicity of this drug in these patient.
- Determine the time to disease progression in patients receiving this drug.
- Determine the overall survival and survival at 1 year in patients receiving this drug.
研究设计
- 研究类型
- Interventional
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
结局指标
主要结局
Confirmed hematologic response
Progression-free survival at 1 year
次要结局
- Toxicity as measured by NCI CTCAE v3.0
- Time to progression
- Duration of response
- Survival
研究者
研究点 (2)
Loading locations...
相似试验
已完成
2 期
Bevacizumab With or Without Thalidomide in Treating Patients With Relapsed or Refractory Multiple MyelomaMultiple Myeloma and Plasma Cell NeoplasmNCT00022607California Cancer Consortium
已完成
2 期
Bevacizumab in Treating Patients With Recurrent or Progressive MeningiomasAdult Anaplastic MeningiomaAdult EpendymomaAdult Grade I MeningiomaAdult Grade II MeningiomaAdult Meningeal HemangiopericytomaAdult Papillary MeningiomaNeurofibromatosis Type 2Recurrent Adult Brain TumorNeurofibromatosis Type 1Acoustic SchwannomaNCT01125046Northwestern University50
已完成
2 期
Bevacizumab and Sorafenib in Treating Patients With Recurrent Glioblastoma MultiformeBrain and Central Nervous System TumorsNCT00621686Alliance for Clinical Trials in Oncology54
已完成
2 期
Bevacizumab, Cisplatin, Etoposide, and Radiation Therapy in Treating Patients With Limited-Stage Small Cell Lung CancerLung CancerNCT00387699Eastern Cooperative Oncology Group79
已完成
2 期
Bevacizumab, Temozolomide, and External Beam Radiation Therapy as First-Line Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or GliosarcomaBrain and Central Nervous System TumorsNCT01013285Jonsson Comprehensive Cancer Center70